PTC Therapeutics
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $211,007 | $178,875 | $1,176,096 | $213,172 |
Gross Profit | 95,068 | 167,455 | 1,163,234 | 196,889 |
EBITDA | 20,627 | -33,111 | 971,141 | -46,875 |
EBIT | 9,518 | -40,694 | 963,920 | -53,639 |
Net Income | 15,896 | -64,849 | 866,562 | -65,886 |
Net Change In Cash | 211,007 | 178,875 | 1,176,096 | 213,172 |
Free Cash Flow | -69,746 | -62,327 | 867,571 | -36,501 |
Cash | 672,617 | 1,017,386 | 1,480,231 | 779,709 |
Basic Shares | 87,115 | 78,151 | 86,385 | 77,201 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $806,780 | $937,822 | $698,801 | $538,593 |
Gross Profit | 749,382 | 872,336 | 654,123 | 506,265 |
EBITDA | -120,463 | -330,340 | -367,780 | -368,184 |
EBIT | -196,126 | -566,930 | -496,616 | -432,318 |
Net Income | -363,295 | -626,604 | -559,017 | -523,901 |
Net Change In Cash | 806,780 | 937,822 | 698,801 | 538,593 |
Cost of Revenue | 101,479 | -11,273 | ||
Free Cash Flow | -181,937 | -279,037 | -509,114 | -336,663 |
Cash | 779,709 | 594,001 | 279,834 | 773,376 |
Basic Shares | 76,845 | 74,838 | 71,728 | 70,466 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-12-31 | $0 |
2025-09-30 | $0.20 |
2025-06-30 | -$0.83 |
2025-03-31 | $10.04 |
